Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Drug

Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022

Fineline Cube Sep 29, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100...

Company

Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics

Fineline Cube Sep 29, 2022

Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a...

Company

Biosyngen to Establish Cell Therapy GMP Facility in Singapore

Fineline Cube Sep 29, 2022

Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...

Company

Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges

Fineline Cube Sep 29, 2022

China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...

Company Medical Device

Parexel Opens Clinical Study Supply Chain Center in Suzhou

Fineline Cube Sep 29, 2022

US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply...

Company Drug

Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043

Fineline Cube Sep 29, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...

Company Drug

Arctic Vision Enrolls First Patient in Phase III Study for ARVN002

Fineline Cube Sep 29, 2022

China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...

Company Deals

3D Medicines Partners with Denfo Medical for Cancer Therapy Development

Fineline Cube Sep 29, 2022

China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...

Company Deals

Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278

Fineline Cube Sep 29, 2022

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...

Company Deals

Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion

Fineline Cube Sep 29, 2022

Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured...

Company

Santen Pharmaceutical Launches New Plant Construction in Suzhou

Fineline Cube Sep 28, 2022

Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu...

Company Drug

Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma

Fineline Cube Sep 28, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...

Company Deals

Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development

Fineline Cube Sep 28, 2022

Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with...

Company Deals

Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China

Fineline Cube Sep 28, 2022

US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement...

Company Drug

NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 28, 2022

The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...

Company

SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 28, 2022

SciClone Pharmaceuticals Inc., formerly a US-based and Nasdaq-listed company that became China-based after going private...

Company Drug

Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China

Fineline Cube Sep 28, 2022

China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...

Company Medical Device

MicroPort CardioFlow’s Alwide Plus Balloon Catheter Approved in Colombia

Fineline Cube Sep 28, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company Deals

Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization

Fineline Cube Sep 28, 2022

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...

Company Drug

Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China

Fineline Cube Sep 28, 2022

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...

Posts pagination

1 … 632 633 634 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.